Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Remission induction in refractory, drug resistant pediatric PICALM::MLLT10+ B-cell acute lymphoblastic leukemia by venetoclax

15 Apr 2025

Abstract excerpt

Acute lymphoblastic leukemia (ALL), with over 80% arising from B-cell lineage precursors (BCP-ALL), is the most common hematologic malignancy in children and adolescents. Intensified treatment strategies have increased survival rates to around 90%. ALL induction therapy according to e.g. the AIEOP-BFM ALL 2017 protocol [ 1 ] combines high-dose steroids, vincristine, daunorubicin and asparaginase and remission is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Acute Myeloid Leukemia Research
Share to Neutropenia and Cancer Infections

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40234615
DOI: 10.1038/s41375-025-02591-w

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Remission induction in refractory, drug resistant pediatric PICALM::MLLT10+ B-cell acute lymphoblastic leukemia by venetoclaxPMID 40234615Read ↗

Venetoclax durable response in adult relapsed/refractory Philadelphia-negative acute lymphoblastic leukemia with JAK/STAT pathway alterationsSemantic proximity Read ↗

Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination TherapiesSemantic proximity Read ↗

Relapsed/Refractory ETP‐ALL Successfully Treated With Venetoclax and Nelarabine as a Bridge to Allogeneic Stem Cell TransplantSemantic proximity Read ↗

Clinical Relevance and Applicability of the 2022 World Health Organization Classification of Childhood B Lymphoblastic Leukemia in the Context of MRD-Directed TherapySemantic proximity Read ↗

Leukemia burden impacts the efficacy and toxicity of blinatumomab in pediatric B-cell acute lymphoblastic leukemiaSemantic proximity Read ↗

Targeting Apoptosis Pathways With BCL2 and MDM2 Inhibitors in Adult B-cell Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Venetoclax-Resistant T-ALL Cells Display Distinct Cancer Stem Cell Signatures and Enrichment of Cytokine SignalingSemantic proximity Read ↗

Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia.Semantic proximity Read ↗

Venetoclax in combination with a pediatric-inspired regimen for the treatment of newly diagnosed adults with Philadelphia chromosome-negative acute lymphoblastic leukemiaSemantic proximity Read ↗

Children’s Oncology Group Blueprint for Research: Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Leukemia burden impacts the efficacy and toxicity of blinatumomab in pediatric B-cell acute lymphoblastic leukemiaSemantic proximity Read ↗

Recent advances in the management of pediatric acute lymphoblastic leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.